This Med-tech company’s turnaround is driven by operational restructuring, a focus on higher-margin U.S. markets, and a patient-first approach under its new CEO; The company has reported two consecutive quarters of profitability, with strong revenue growth and flat operating expenses; We expect a near-term upside of at least 100%; Key catalysts include continued sales and EPS growth, as well as the divestiture of part of the business.